Importantly, the mTOR pathway inhibitor rapamycin shows a synergistic effect with ATO in the induction of NETosis-mediated elimination of leukemia-initiating cells (LICs) in APL cells and in an APL model in vivo [84]. The gene discussed is MTOR; the disease is acute promyelocytic leukemia.